MEDP
MedpaceCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Medpace converts partnership wins into higher backlog conversion and margin expansion; sustained demand for complex oncology trials and disciplined cost control push earnings above consensus.
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -2.2.
What can break
Client concentration / large-client loss
Momentum
18
Value
63
Sentiment
84
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $614.16 · Bull $760.38 · Bear $438.68
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-05-29 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2025-11-03 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $503.00
Why
Momentum18 · Δ7d +7.0
Value63 · Δ7d +0.1
Sentiment84 · Δ7d -2.2
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Sentiment · See AI snapshot
Momentum
18
34% active weight
Current posture
7d trendImproving
Δ7d
+7.0
Δ21d
+13.6
Value
63
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.1
Sentiment
84
33% active weight
Current posture
7d trendSoftening
Δ7d
-2.2
Δ21d
-1.1
Why this grade
Composite grade C. Momentum 18.4 / Value 62.8 / Sentiment 84.0
Fundamentals (TTM)As of 2026-05-29
Fundamentals (TTM)
As of 2026-05-29
Market Cap
$12.77B
Beta
1.42
Shares Out
28.1M
P/E (TTM)
41.0
P/S (TTM)
7.01
P/FCF (TTM)
24.42
Rev YoY
+23.7%
EPS YoY
+28.3%
Gross Margin
+31.1%
Op Margin
+21.5%
Net Debt
-$669.44M
Current Ratio
0.57
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology